Hemopexin is up-regulated in plasma from type 1 diabetes mellitus patients: Role of glucose-induced ROS

Type 1 diabetes mellitus (T1DM) is an insulin-dependent metabolic disease in the world and often occurs in children and adolescents. Recent advances in quantitative proteomics offer potential for the discovery of plasma proteins as biomarkers for tracking disease progression and for understanding the molecular mechanisms of diabetes. Comparative proteomic analysis of the plasma proteomes from T1DM cases and healthy donors with lysine- and cysteine-labeling 2D-DIGE combining MALDI–TOF/TOF mass spectrometry revealed that 39 identified T1DM-associated plasma proteins showed significant changes in protein expression including hemopexin, and 41 in thiol reactivity. Further study showed that hemopexin can be induced in numerous cell lines by increasing the glucose concentration in the medium. Interestingly, glucose-induced hemopexin expression can be reduced by reactive oxygen species (ROS) scavengers such as glutathione, implying that hemopexin expression is linked to glucose-induced oxidative stress. In conclusion, the current work has identified potential T1DM biomarkers and one of these, hemopexin, can be modulated by glucose through a ROS-dependent mechanism.

2D-DIGE comparative analysis of plasma from type 1 diabetes mellitus cases and healthy controls.Figure optionsDownload high-quality image (253 K)Download as PowerPoint slideHighlights
► Type 1 diabetes mellitus (T1DM) is an insulin-dependent metabolic disease.
► Plasma proteomic analysis were performed with lysine- and cysteine-labeling 2D-DIGE.
► 39 and 41 proteins showed alterations in protein expression and thiol reactivity, respectively.
► Expression of hemopexin was modulated by glucose through ROS-dependent mechanism.